Combination
US10172914B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Aug 9, 2017 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | Aug 9, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/605
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a combination comprising at least two of the following: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist, for instance a combination comprising at least two of (i) exenatide, or a functional derivative or analog thereof, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analog thereof, or a pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analog thereof. Said combinations are suitable for cardioprotection and for treating and/or preventing ischemia and/or reperfusion injury. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.